PROFARMA (2017-2020): Promoting competitiveness in the Pharmaceutical Industry

The PROFARMA plan - Promotion of competitiveness in the pharmaceutical industry - is aimed at companies that manufacture or market medicines for human use and that carry out R&D&i activities in the national territory.

 The programme is coordinated by three Ministries: The Ministry of Industry, Trade and Tourism, the leader of the Plan; the Ministry of Health, Consumption and Social Welfare; and the Ministry of Science, Education and Universities.

The plan seeks to favour the competitiveness of the pharmaceutical sector in our country, promoting the activities that provide companies with added value, fundamentally Research, Development and Technological Innovation activities, as well as industrial investments in production plants.

PROFARMA (2017-2020)

In the previous call, PROFARMA 2017, a total of 55 companies applied. Nine of them were rated as "excellent", six national (Almirall, Grifols, Grupo Ferrer, Laboratorios Esteve, Rovi and Pharma Mar) and three international (Glaxosmithkline, Lilly and Novartis). All of them have been included in the highest category since 2006.

 The deadline for submission of applications to PROFARMA 2019 is 29 May.